Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that members of its Executive Management Team will participate
in a fireside chat at the Goldman Sachs 40th Annual
Healthcare Conference on Wednesday, June 12, 2019 at 9:20 a.m. P.D.T. in
Rancho Palos Verdes, California.
A live webcast of the fireside chat will be accessible on the Events
page under the Investor Relations section of the Aimmune website at www.aimmune.com.
A replay will also be available following the webcast.
About Aimmune
Aimmune Therapeutics, Inc., is a biopharmaceutical company developing
oral treatments for life-threatening food allergies. The company's Characterized
Oral Desensitization
ImmunoTherapy
(CODITtm) approach is intended to provide meaningful levels of protection
against allergic reactions resulting from exposure to food allergens by
desensitizing patients with defined, precise amounts of key allergens.
Aimmune's first, investigational, complex biologic product, AR101, is
being developed as a treatment to reduce the frequency and severity and
adverse events following exposure to peanut. The BLA for AR101 is under
review by the FDA, which granted AR101 Breakthrough Therapy Designation
in 2015 for the desensitization of peanut-allergic patients 4 to 17
years of age. The Allergenic Products Advisory Committee (APAC) of the
FDA will review the BLA for AR101 at a meeting scheduled for September
13, 2019. Aimmune has filed an IND application for its second product,
AR201 for the treatment of egg allergy, and intends to start a
randomized phase 2 clinical trial in mid-2019. For more information,
please see www.aimmune.com.
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024. At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...
César A. Lara, MD, introduces a groundbreaking solution for pain relief in the Tampa Bay area. Red Laser Therapy leverages the power of medical-grade red laser light to effectively address various types of pain, providing patients with a noninvasive...